DK1723144T3 - Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister - Google Patents

Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister

Info

Publication number
DK1723144T3
DK1723144T3 DK05802855.6T DK05802855T DK1723144T3 DK 1723144 T3 DK1723144 T3 DK 1723144T3 DK 05802855 T DK05802855 T DK 05802855T DK 1723144 T3 DK1723144 T3 DK 1723144T3
Authority
DK
Denmark
Prior art keywords
additional
receptor antagonists
glutamate receptor
metabotropic glutamate
compounds
Prior art date
Application number
DK05802855.6T
Other languages
English (en)
Inventor
Louise Edwards
Methvin Isaac
Martin Johansson
Annika Kers
Johan Malmberg
Donald Mcleod
Alexander Minidis
Karin Staaf
Abdelmalik Slassi
Tomislav Stefanac
Thomas Stormann
David Wensbo
Tao Xin
Jalaj Arora
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1723144T3 publication Critical patent/DK1723144T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05802855.6T 2004-02-18 2005-02-15 Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister DK1723144T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60896004P 2004-02-18 2004-02-18
PCT/US2005/004774 WO2006014185A1 (en) 2004-02-18 2005-02-15 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
DK1723144T3 true DK1723144T3 (da) 2011-01-03

Family

ID=35447957

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05802855.6T DK1723144T3 (da) 2004-02-18 2005-02-15 Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister

Country Status (27)

Country Link
US (6) US7585881B2 (da)
EP (2) EP2311830A1 (da)
JP (1) JP4912157B2 (da)
CN (2) CN1984907A (da)
AT (1) ATE483706T1 (da)
AU (1) AU2005270208A1 (da)
BR (1) BRPI0507497A (da)
CA (1) CA2555566A1 (da)
CY (1) CY1110965T1 (da)
DE (1) DE602005023963D1 (da)
DK (1) DK1723144T3 (da)
ES (1) ES2352110T3 (da)
HK (1) HK1099285A1 (da)
HR (1) HRP20100654T1 (da)
IL (1) IL177394A0 (da)
NO (1) NO20063599L (da)
NZ (1) NZ548954A (da)
PL (1) PL1723144T3 (da)
PT (1) PT1723144E (da)
RS (1) RS51516B (da)
RU (1) RU2370495C2 (da)
SG (1) SG146657A1 (da)
SI (1) SI1723144T1 (da)
UA (1) UA84318C2 (da)
UY (1) UY28766A1 (da)
WO (1) WO2006014185A1 (da)
ZA (1) ZA200606551B (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87653C2 (en) * 2002-08-09 2009-08-10 Астразенека Аб 1,2,4-oxadiazols as modulators of receptor-5 for metabotropic glutamate
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2005236020A1 (en) * 2004-04-20 2005-11-03 Merck & Co., Inc. 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
JPWO2006080533A1 (ja) * 2005-01-31 2008-06-19 持田製薬株式会社 ３−アミノ−１，２，４−トリアゾール誘導体
AR058807A1 (es) * 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200811179A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators VI
CA2657247A1 (en) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
AU2008257559B2 (en) * 2007-05-25 2013-10-10 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor)
US20100144756A1 (en) * 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
CL2008003085A1 (es) * 2007-10-19 2009-10-09 Astrazeneca Ab Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054786A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
EP2217565B1 (en) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
JP2011513398A (ja) * 2008-03-03 2011-04-28 スティーフェル ラボラトリーズ インコーポレイテッド 鏡像異性的に純粋なジオールおよびジオキソラン化合物の製造方法
MY172105A (en) 2008-05-14 2019-11-14 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
WO2010005782A1 (en) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
KR20110040910A (ko) * 2008-08-12 2011-04-20 아스트라제네카 아베 4-(5-((1ｒ)-1-[5-(3-클로로페닐)이속사졸-3-일]에톡시)-4-메틸-4ｈ-1,2,4-트리아졸-3-일)피리딘의 결정질 형태
KR20110044864A (ko) * 2008-08-12 2011-05-02 아스트라제네카 아베 4-(5-((1ｒ)-1-[5-(3-클로로페닐)이속사졸-3-일]에톡시)-4-메틸-4ｈ-1,2,4-트리아졸-3-일)피리딘의 신규 결정질 형태
JP5453437B2 (ja) 2008-09-25 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節するスルホニル化合物
JP2012512868A (ja) * 2008-12-18 2012-06-07 アストラゼネカ・アクチエボラーグ ３−｛４−メチル−５−［（１ｒ）−１−（２−（３−メチルフェニル−２ｈ−テトラゾール−５−イル）−エトキシ］−４ｈ−［１，２，４］トリアゾール−３−イル｝−ピリジン、４−メチル−３−メチルチオ−５−（３−ピリジル）−１，２，４−トリアゾール、および（１ｒ）−１−［２−（３−メチルフェニル）−２ｈ−テトラゾール−５−イル］エタノールの製造方法
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010096371A2 (en) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the cb2 receptor
WO2010114971A1 (en) * 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
EP2438052A1 (en) 2009-06-05 2012-04-11 Oslo University Hospital HF Azole derivatives as wtn pathway inhibitors
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
EP2480544A1 (en) * 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
BR112012011427B8 (pt) 2009-11-13 2021-05-25 Celgene Int Ii Sarl moduladores seletivos de receptor de esfingosina 1 fosfato, seu uso, e composição
CN102753022B (zh) * 2009-11-13 2016-04-20 瑞塞普托斯公司 选择性的杂环1-磷酸鞘氨醇受体调节剂
CN102724880B (zh) 2009-11-13 2016-09-14 瑞塞普托斯有限责任公司 1-磷酸鞘氨醇受体调节剂及手性合成方法
CN101712641B (zh) * 2009-12-29 2013-05-08 江苏工业学院 一种甲硫基苯甲酸的制备方法
JP5775094B2 (ja) * 2009-12-29 2015-09-09 イーライ リリー アンド カンパニー 統合失調症の処置に有用な選択的ｍＧｌｕ５受容体増強因子としてのテトラヒドロトリアゾロピリジン化合物
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
WO2012058128A2 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Caprolactam mglur5 receptor modulators
CA2820800A1 (en) 2010-12-08 2012-06-14 Oslo University Hospital Hf Triazole derivatives as wnt signaling pathway inhibitors
DE102010063974B4 (de) * 2010-12-22 2021-10-07 Thomas Rühl Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
US8759380B2 (en) * 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
MX365218B (es) 2013-09-06 2019-05-27 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores.
JP6858129B2 (ja) * 2015-03-05 2021-04-14 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換されたフェニルイソオキサゾリン誘導体の製造方法
CN107427477B (zh) 2015-03-10 2021-11-26 奥瑞基尼探索技术有限公司 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
KR20170123317A (ko) * 2015-03-10 2017-11-07 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서의 3-치환된-1,2,4-옥사다이아졸 및 티아다이아졸 화합물
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
EP3694841A1 (en) 2017-10-11 2020-08-19 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
KR20200083503A (ko) 2017-11-03 2020-07-08 오리진 디스커버리 테크놀로지스 리미티드 Tim-3 경로와 pd-1 경로의 이중 저해제
CN111386128A (zh) 2017-11-06 2020-07-07 奥瑞基尼探索技术有限公司 用于免疫调节的联合疗法
CN111448181B (zh) * 2017-11-16 2023-05-19 蒙特多力士有限公司 单脒和二脒核酸内切-外切酶抑制剂和抑制核酸内切-外切酶活性的方法
EP3860989B1 (en) 2018-10-05 2023-04-05 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
KR20210114457A (ko) 2019-01-15 2021-09-23 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
EP3962481A4 (en) * 2019-05-03 2023-03-22 Praxis Precision Medicines, Inc. KCNT1 INHIBITORS AND METHODS OF USE
TW202140437A (zh) * 2020-01-07 2021-11-01 美商達薩瑪治療公司 Sarm1抑制劑
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4538833A (en) * 1983-12-08 1985-09-03 P I E International Inc. Publication
US5403138A (en) * 1991-10-09 1995-04-04 Fuji Photo Film Co., Ltd. Booklet album including a double-sided photograph and a method of making the same
US5332265A (en) * 1993-01-22 1994-07-26 Minnesota Mining And Manufacturing Company Advertising assembly
CZ2002599A3 (cs) 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
JP2005516950A (ja) 2001-12-19 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 代謝型グルタミン酸受容体−５のヘテロアリール置換イミダゾールモジュレータ
EP1536790A2 (en) 2002-08-09 2005-06-08 AstraZeneca AB Oxadiazoles as modulators of metabotropic glutamate receptor-5
UA87653C2 (en) 2002-08-09 2009-08-10 Астразенека Аб 1,2,4-oxadiazols as modulators of receptor-5 for metabotropic glutamate
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AR058807A1 (es) * 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5

Also Published As

Publication number Publication date
IL177394A0 (en) 2006-12-10
US20080015234A1 (en) 2008-01-17
US20070293545A1 (en) 2007-12-20
RU2370495C2 (ru) 2009-10-20
US20080045571A1 (en) 2008-02-21
RU2006128446A (ru) 2008-03-27
PT1723144E (pt) 2010-12-07
SG146657A1 (en) 2008-10-30
CA2555566A1 (en) 2006-02-09
ATE483706T1 (de) 2010-10-15
JP4912157B2 (ja) 2012-04-11
CY1110965T1 (el) 2015-06-11
SI1723144T1 (sl) 2011-01-31
AU2005270208A1 (en) 2006-02-09
CN101096368A (zh) 2008-01-02
DE602005023963D1 (de) 2010-11-18
UA84318C2 (ru) 2008-10-10
NO20063599L (no) 2006-10-27
HK1099285A1 (en) 2007-08-10
BRPI0507497A (pt) 2007-07-10
US20080015204A1 (en) 2008-01-17
PL1723144T3 (pl) 2011-02-28
EP1723144A1 (en) 2006-11-22
JP2007523168A (ja) 2007-08-16
WO2006014185A1 (en) 2006-02-09
US7585881B2 (en) 2009-09-08
RS51516B (en) 2011-06-30
US20070179188A1 (en) 2007-08-02
ES2352110T3 (es) 2011-02-15
ZA200606551B (en) 2007-11-28
US20050272779A1 (en) 2005-12-08
EP2311830A1 (en) 2011-04-20
HRP20100654T1 (hr) 2011-01-31
CN1984907A (zh) 2007-06-20
NZ548954A (en) 2009-07-31
EP1723144B1 (en) 2010-10-06
UY28766A1 (es) 2005-08-31

Similar Documents

Publication Publication Date Title
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
NO20033711L (no) Heteropolysykliske forbindelser og deres anvendelse som metabotrope glutamatatreseptorantagonister
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
GB0504828D0 (en) Therapeutic agents
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
HK1101178A1 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MX2007014405A (es) Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
GT200500309A (es) Derivados de sulfonilbencilimidazol
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
SE0400043D0 (sv) New compounds
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
HK1116477A1 (en) Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
MX2008001608A (es) Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
MX2008001607A (es) Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico.
MY148488A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
PA8545601A1 (es) Derivados de 4-aminopirimidina
SE0403118D0 (sv) New compounds 2
NO20081529L (no) Naftyridinderivater
ATE417039T1 (de) 3,4-dihydro-2-naphthoesäureamidderivate und deren therapeutische anwendungen